



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Antonio Gonzalez (Spain)  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editor**  
Ane Gerda Zahl Eriksson (Norway)

**Managing Editor**  
Lindsey Struckmeyer (USA)

**Editorial Office**  
International Journal of Gynecological Cancer, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jmeditorial.com](mailto:ijgc@jmeditorial.com)

**Production Editor**  
Hannah Martin  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with existing and new subscriptions:  
W: [support.bmj.com](http://support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/products-services/rights-and-licensing/](http://bmj.com/company/products-services/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

The *International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Lead article

- 1471** Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: an international survey of peri-operative practice  
*G P Bhandoria, P Bhandarkar, V Ahuja, A Maheshwari, R K Sekhon, M Gultekin, A Ayhan, F Demirkiran, I Kahramanoglu, Y-L L Wan, P Knapp, J Dobroch, A Zmazyński, R Jach, G Nelson*

## Editorial

- 1479** Knowing but not doing: the state of global enhanced recovery after surgery in gynecologic oncology  
*K Elias*

## Cervical Cancer

- 1480** Limited frequency of malignant change in lobular endocervical glandular hyperplasia  
*H Kobara, T Miyamoto, H Ando, R Asaka, A Takatsu, A Ohya, S Asaka, T Shiozawa*
- 1488** Real time quantitative methylation detection of PAX1 gene in cervical cancer screening  
*H Liu, X Meng, J Wang*

- 1493** Prognostic value of lymphovascular space invasion in early-stage cervical cancer  
*A Weyl, C Illac, A Lusque, H Leray, C Vaysse, A Martinez, E Chantalat, S Motton*

- 1500** Characterization of vaginal microbiota in Chinese women with cervical squamous intra-epithelial neoplasia  
*M Wu, J Gao, Y Wu, Y Li, Y Chen, F Zhao, C Li, C Ying*

- 1505** External beam radiation and brachytherapy boost at different facilities is associated with increased treatment delays in cervical cancer  
*R Li, E Germino, Z D Horne, J A Vargo, Y-J Chen, S Glaser*

## Uterine Cancer

- 1513** Impact of hysteroscopy on course of disease in high-risk endometrial carcinoma  
*A Larish, A Kumar, A Weaver, A Mariani*

- 1520** Prognostic nomogram for predicting survival in patients with high grade endometrial stromal sarcoma: a Surveillance Epidemiology, and End Results database analysis  
*J Wu, H Zhang, L Li, M Hu, L Chen, S Wu, B Xu, Q Song*

- 1528** Clinical relevance of high–intermediate risk endometrial cancer according to European risk classification  
*A Rychlik, I Zapardiel, L Baquedano, M Á Martínez Maestre, D Querleu, P J Coronado Martín*

- 1535** Outcomes and toxicity after salvage radiotherapy for vaginal relapse of endometrial cancer  
*L G Sapienza, M S Ning, R de la Pena, L K McNew, A Jhingran, L Georgeon, N Rasool, M J L Gomes, E Abu-Isa, G Baiocchi*

## Ovarian Cancer

- 1542** Appendectomy at the time of ovarian cancer staging increases infectious complications: a National Surgical Quality Improvement Program (NSQIP) propensity score-stratified analysis  
*L Bernard, I Chen, T Le*

- 1548** LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial  
*A Hasenburg, J Sehouli, B Lampe, A Reuss, B Schmalfeld, A K Belau, M Bossart, S Mahner, P Hillemanns, U Petry, A du Bois, U Herwig, F Hilpert, M Gropp-Meier, V Hanf, E Greimel, U Wagner, P Harter*

- 1554** Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer  
*Y L Liu, Q C Zhou, A Iasonos, O T Filippova, D S Chi, O Zivanovic, Y Sonoda, G Gardner, V Broach, R OCearbhaill, J A Konner, C A Aghajanian, K Long, W Tew*

- 1562** Value of pre-existent bacterial colonization in patients with advanced/relapsed ovarian neoplasms undergoing cytoreductive surgery: a multicenter observational study (BONSAI)  
*C Fotopoulou, N Rinne, V Ghirardi, P Cunnea, A Drosou, D Tzovaras, M T Giudice, G Scambia, A Fagotti*

- 1569** Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis

*D A Barrington, C Tubbs, H J Smith, J M Straughn, Jr, L Senter, D E Cohn*

- 1576** Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis

*H Gong, D Nie, Y Huang, Z Li*

- 1583** Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices

*C H Watson, L Soo, B A Davidson, L J Havrilesky, P S Lee, L J McNally, R A Previs, A A Secord, A Berchuck, N D Kauff*

---

## Surgery

- 1589** Perioperative management of positioning in gynecological cancersurgery: a national NOGGO-AGO intergroup survey

*M Bommer, J K Wagner, J Schouli, A Burges, B Schmalfeld, H Veldink, I Schrettenbrunner, M Fleisch, R Richter, P Harter, K Pietzner*

- 1595** Enhanced recovery for obese patients undergoing gynecologic cancer surgery

*R Harrison, M D Iniesta, B Pitcher, P T Ramirez, K Cain, A M Siverand, G Mena, J Lasala, L A Meyer*

---

## Quality of Life

- 1603** Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment

*R Armbrust, S Alavi, A Pirmorady, F Chen, N Colombo, M Gultekin, C Hierro, B Lemley, M R Mirza, E Urkmez, C Fotopoulou, J Vinzent, A Gonzalez Martin, A Krull, J Heepe, M Rose, J Schouli*

---

## Reviews

- 1608** The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers

*A Chelariu-Raicu, G Zibetti Dal Molin, R L Coleman*

- 1619** Low-grade serous ovarian carcinoma: an evolution toward targeted therapy

*I A Voutsadakis*

---

## Clinical trial

- 1627** A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial)

*T Grassi, A Mariani, D Cibula, P T Soliman, V J Suman, A L Weaver, S Pedra Nobre, B Weigelt, G E Glaser, S Cappuccio, N R Abu-Rustum*

- 1633** A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)

*I Ray-Coquard, H Hatcher, E Bompas, A Casado, A Westermann, N Isambert, P G Casali, S Pratap, D Starke, C Valverde, A Anand, M Huizing, A Floquet, L Lindner, B Hermes, B Seddon, C Coens, R Jones, N Reed*

---

## Case study

- 1638** Infection versus cancer: management of actinomyces mimicking cervical cancer or ovarian cancer

*D Odetto, M Perrotta, J M Saadi, C B Chacon, P I Causa Andrieu, A Wernicke, M C Saez Perrotta*

---

## Corners of the world

- 1644** EnganCHADos-Bebedjia hospital (Chad) and Fuenlabrada hospital (Madrid): improving surgical care in gynecological oncology

*R Montero-Macías, E Raule, J De La Torre González, D Huerga Álvarez, A Antequera Pérez*

---

**Video articles**

- 1646** Transdiaphragmatic and transxiphoid cardiophrenic lymph node resection step-by-step in advanced ovarian cancer

*C Martínez-Gómez, M A Angeles, H Leray, Y Tanguy Le Gac, G Ferron, A Martínez*

- 1648** Upper abdominal debulking surgery for ovarian cancer total colectomy, total peritonectomy, and extended upper abdominal debulking surgery

*C Taskiran, D Vatanserver, B Giray, A Eraslan, S Tanju, M Arvas, E Balik*

- 1650** Double-barrel wet colostomy after total pelvic exenteration

*V Lago, T Marina, F Delgado Oliva, P Padilla-Iserte, L Matute, S Domingo*

- 1652** Simple trachelectomy with laparoscopic pelvic lymphadenectomy in a pregnant woman with a FIGO stage IA2 cervical cancer

*M Perrotta, F Noll, J P S Cortez, L Bolaño, J M Saadi, D Odetto*

---

**Commentary**

- 1654** Immunotherapy in gestational trophoblastic neoplasia: great times are coming

*E Paulino, A C de Melo*

---

**Letter**

- 1656** Cisplatin? Why not?

*A M Perrone, G Corrado, P De Iaco*